Robot arm steadies eye surgery for bleeding behind the retina

NCT ID NCT06347107

Completed Disease control Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a robotic stabilizer to help surgeons inject a clot-busting drug (tPA) under the retina in 20 patients with bleeding from age-related macular degeneration. The robot held the needle steady for up to 3 minutes during standard surgery. The main goals were to see if the needle could be placed correctly and stay still, and to check for device-related side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tissue plasminogen activator (tPA)
What this could lead to: If successful, this robotic approach could make subretinal injections more precise and stable, potentially improving outcomes for people with bleeding under the retina.
What could go wrong: This was a small, early-stage study with only 20 participants and no control group. The device is a prototype, and results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

UZ Leuven

Leuven, Vlaams-Brabant, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.